Medicine
Xpovio 40 mg tablet
Xpovio 40 mg tablet is a prescription medicine containing Selinexor for oral use, marketed by Karyopharm Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at or below 30°C (86°F).
Key facts
- Active ingredient (INN)
- Selinexor
- Brand
- Xpovio
- Strength
- 40 mg
- Dosage form
- Tablet
- Route
- Oral
- Packs
- 4 blister pack
- Marketing authorisation holder
- Karyopharm Therapeutics
- Manufacturer
- Karyopharm Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store at or below 30°C (86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- L01XX66 Selinexor
- HS code (indicative)
- 3004.90Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 19 May 2021
- Identifiers
- RxCUI 2178395, 2178402, 2178406 +7DailyMed set ID f6dd2682-75a6-4863-90a8-a3197f6f78a8NDC 72237-102Application NDA212306
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 4 blister pack in 1 carton / 2 tablet, film coated in 1 blister pack | 72237-102-02 | Karyopharm Therapeutics | 19 May 2021 |
| 4 blister pack in 1 carton / 2 tablet, film coated in 1 blister pack | 72237-102-06 | Karyopharm Therapeutics | 19 May 2021 |
| 4 blister pack in 1 carton / 1 tablet, film coated in 1 blister pack | 72237-102-07 | Karyopharm Therapeutics | 19 May 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Selinexor
Clinical summary
Selinexor is a nuclear export inhibitor indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy, among other approved uses. MedsAcross supplies Selinexor for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about SelinexorFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- XPOVIO prescribing information (Karyopharm Therapeutics) · U.S. National Library of Medicine, DailyMed
- Nexpovio: European public assessment report (EPAR) · European Medicines Agency
Need Xpovio 40 mg tablet for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.